Drug Trial Radar · NCT03400800
Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
Last checked: Nov 19, 2026Latest source record: Aug 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,617
Actual
Start
Nov 1, 2017
Primary completion
Jul 31, 2019
Study completion Aug 27, 2019
Sponsor
- Lead sponsor
- The Medicines CompanyIndustry
- Sponsor type
- Industry
- First posted
- Jan 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD or ASCVD-Risk equivalents and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s). The study will be an international multicenter study (non-United States).
Conditions
- ASCVD
- Risk Factor, Cardiovascular
- Elevated Cholesterol
Interventions
Inclisiran SodiumDrug
Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
PlaceboDrug
Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change in LDL-C From Baseline to Day 510Time frame: Baseline, Day 510
- Time-adjusted Percent Change in LDL-C Levels From Baseline After Day 90 and up to Day 540Time frame: Baseline, Day 90 to Day 540
Locations
70 sites in 7 countries. Site status is shown where the registry gives one.
Research Site 11420-002
Chomutov, Czechia
Research Site 11420-003
Uherské Hradiště, Czechia
Research Site 11049-006
Berlin, Germany
Research Site 11049-002
Bochum, Germany
Research Site 11049-003
Frankfurt, Germany
Research Site 11049-007
Heidelberg, Germany
Research Site 11049-001
Leipzig, Germany
Research Site 11036-001
Budapest, Hungary
Research Site 11036-004
Debrecen, Hungary
Research Site 11036-002
Hatvan, Hungary
Research Site 11036-003
Zalaegerszeg, Hungary
Research Site 11048-011
Bydgoszcz, Poland
Research Site 11048-004
Gdansk, Poland
Research Site 11048-017
Gdansk, Poland
Research Site 11048-005
Gdynia, Poland
Research Site 11048-007
Katowice, Poland
Research Site 11048-012
Katowice, Poland
Research Site 11048-014
Krakow, Poland
Research Site 11048-003
Krakow, Poland
Research Site 11048-008
Lublin, Poland
Research Site 11048-001
Poznan, Poland
Research Site 11048-013
Rzeszów, Poland
Research Site 11048-015
Tarnów, Poland
Research Site 11048-009
Warsaw, Poland
Research Site 11048-006
Warszawice, Poland
Research Site 11048-002
Wroclaw, Poland
Research Site 11048-010
Wroclaw, Poland
Research Site 11048-018
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Research Site 11048-016
Brzozów, Podkarpackie Voivodeship, Poland
Research Site 11048-019
Ruda Śląska, Silesian Voivodeship, Poland
Research Site 11027-006
Pretoria, South Africa
Research Site 11027-011
Welkom, South Africa
Research Site 11027-003
Bloemfontein, Free State, South Africa
Research Site 11027-005
Johannesburg, Gauteng, South Africa
Research Site 11027-001
Cape Town, Western Cape, South Africa
Research Site 11027-013
Cape Town, Western Cape, South Africa
Research Site 11027-007
Kuils River, Western Cape, South Africa
Research Site 11027-004
Somerset West, Western Cape, South Africa
Research Site - 11380-005
Cherkasy, Ukraine
Research Site - 11380-008
Kharkiv, Ukraine
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.